TY - JOUR T1 - Mechanisms of Arrhythmogenicity in Hypertrophic Cardiomyopathy: Insight from Noninvasive Electrocardiographic Imaging JF - medRxiv DO - 10.1101/19002782 SP - 19002782 AU - Erick A. Perez-Alday AU - Kazi T. Haq AU - David M. German AU - Christopher Hamilton AU - Kyle Johnson AU - Francis Phan AU - Nichole M. Rogovoy AU - Katherine Yang AU - Ashley Wirth AU - Jason A.Thomas AU - Khidir Dalouk AU - Cristina Fuss AU - Maros Ferencik AU - Stephen Heitner AU - Larisa G. Tereshchenko Y1 - 2019/01/01 UR - http://medrxiv.org/content/early/2019/07/22/19002782.abstract N2 - Background Mechanisms of arrhythmogenicity in hypertrophic cardiomyopathy (HCM) are not well understood. We hypothesized that HCM is characterized by the specific electrophysiological substrate as compared to patients with ischemic cardiomyopathy (ICM), or healthy individuals.Methods We conducted a prospective case-control study. HCM patients at high risk for ventricular tachyarrhythmia (VT) (n=10; age 61±9 y; left ventricular ejection fraction (LVEF) 60±9%) and three control groups (Healthy individuals (n=10; age 28±6 y; LVEF>70%), ICM patients with LV hypertrophy (LVH) and known VT (n=10; age 64±9 y; LVEF 31±15%), and ICM patients with LVH, and no known VT (n=10; age 70±7y; LVEF 46±16%). All participants underwent 12-lead ECG, cardiac CT or MRI, and 128-electrode body surface mapping (BioSemi ActiveTwo, Netherlands). Non-invasive voltage and activation maps were reconstructed using the open-source SCIRun (University of Utah) inverse problem-solving environment.Results In endocardial basal anterior segment, HCM patients had the slowest ventricular conduction [54.3±8.6 vs. 64.0±8.0 (ICM with VT) vs. 63.3±5.4 (ICM no VT) vs. 66.1±5.4 cm/s (Healthy); P=0.019], the largest unipolar voltage [1086±241 vs. 982±230 (ICM with VT) vs. 853±281 (ICM no VT) vs. 802±108 µV (Healthy); P=0.016], and the greatest voltage dispersion [median(interquartile range) 178(162-276) vs. 146(89-157) (ICM with VT) vs. 161(102-214) (ICM no VT) vs. 101(53-147) µV (Healthy); P=0.017]. Differences were also observed in other endo-and epicardial basal and apical segments.Conclusion Ventricular conduction velocity is slower in HCM when compared with ICM, even in myocardial segments remote from the region of maximal wall thickness, suggesting a distinct electrophysiological substrate in HCM.Clinical Trial Registration URL: www.clinicaltrials.gov Unique identifier: NCT02806479Competing Interest StatementThe study was funded by Gilead Sciences, Inc, as physician-initiated study (LGT).Clinical TrialNCT02806479Funding StatementThe study was funded by Gilead Sciences, Inc, as a physician-initiated study. This work was partially supported by 1R01HL118277 and 2R56HL118277 (LGT).Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.YesI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.Not Applicablen/a ER -